Market
Highlights
The
increasing prevalence of breast cancer, growing geriatric population, rising
healthcare expenditures, and increasing R&D expenses by the key players are
estimated to drive the market growth during the forecast period. However,
factors such as lack of healthcare services in low-income countries, the high
cost of treatment, and related side effects are estimated to restrain the
market growth during the forecast period.
Request
For Sample Report: https://www.marketresearchfuture.com/sample_request/5776
Segmentation
The
global bone metastasis market is segmented on the basis of type, diagnosis,
treatment, and end-user.
On
the basis of type, the market is segmented into osteolytic bone metastasis,
osteoblastic bone metastasis, mixed bone metastasis, and others. On the basis
of diagnosis, the market is categorized into biopsy, blood test, imaging, and
others. The imaging segment is sub-segmented into X-ray, bone scintigraphy,
computerized tomography, magnetic resonance imaging, positron emission
tomography, and others. On the basis of treatment, the market is segmented into
medical therapies, surgery, medication, and others. The medical therapies
segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy,
ablation therapy, and others. The surgery segment is sub-segmented into
vertebroplasty, kyphoplasty, and others. The medication segment is
sub-segmented into pain medications, bone building medications, and others. On
the basis of end-user, the market is segmented into hospitals and clinics,
diagnostic centers, pharmacies, and ambulatory surgical centers.
Regional
Analysis
America
dominates the global bone metastasis market owing to the presence of a
well-developed healthcare sector, increasing prevalence of breast cancer, and
rising healthcare sector within the region. Europe stands second in the market
and is followed by Asia Pacific owing to the availability of funds for research
and a huge patient population. Europe is segmented into Western Europe and
Eastern Europe. Western Europe leads the regional market due to the presence of
developed economies such as Italy, Germany, France, and others within the
region. Asia Pacific is projected to be the fastest growing region in the
global bone metastasis market. The presence of a developing healthcare sector
and increasing prevalence of cancer are expected to be the major drivers for
the market growth during the forecast period. The Middle East and Africa holds
the least share in the market. This can be attributed to the presence of poor
economies, stringent government policies, and lack of healthcare services,
especially within the African region.
Key
Players
The
key players in the global bone metastasis market are F. Hoffmann-La Roche Ltd
(Switzerland)
Bayer AG (Germany), Merck & Co., Inc.
(U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc.
(England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.),
Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others.
No comments:
Post a Comment